ReviewClinical microbiology reviews2022
SARS-CoV-2 Infection and Lung Regeneration.
Review in Clinical microbiology reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06492798 (Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients
Who cites it
39 citing papers in PubMed, 53 citations in OpenAlex.
- Efficacy and safety of combined nebulization of unfractionated heparin, acetylcysteine, budesonide and ipratropium bromide in hospitalised patients with COVID-19 pneumonia: a randomized controlled clinical trial.BMC pulmonary medicine · 2025Trial
- Impact of SARS-CoV-2 infection history on the clinical features and outcomes of patients with recurrent pulmonary tuberculosis: a retrospective case-control study.Annals of medicine · 2026Article
- Delayed antiviral immune response in alveolar type 2 cells increases susceptibility to influenza virus in alveoli.Chinese medical journal · 2026Article
- Annotation-free phenotype prediction using knowledge-augmented clustering from single-cell RNA sequencing data.Briefings in bioinformatics · 2026Article
- Anti-vimentin antibody mitigates SARS-CoV-2 spike protein-induced fibroblast activation and fibrosis.American journal of respiratory cell and molecular biology · 2026Article
- A narrative review of SARS-CoV-2 variants and long COVID.Journal of thoracic disease · 2026Review
- Amplified inflammatory and immune responses in viral-associated pulmonary aspergillosis.Frontiers in cellular and infection microbiology · 2026Article
- Multi-omics analysis reveals distinct spatial compartmentalization of lung repair niches in pediatric ARDS.Journal of translational medicine · 2025Article
- High-throughput isolation of normal and pulmonary fibrosis human alveolar epithelial cells.Scientific reports · 2025Article
- Biomimetic targeted self-adaptive nanodrug for inflammation optimization and AT2 cell modulation in precise ARDS therapy.Science advances · 2025Article
- Health outcomes one year after Omicron infection among 12,789 adults: a community-based cross-sectional study.The Lancet regional health. Western Pacific · 2025Article
- Respiratory long COVID in aged hamsters features impaired lung function post-exercise with bronchiolization and fibrosis.Nature communications · 2025Article
- Establishment of a bat lung organoid culture model for studying bat-derived infectious diseases.Scientific reports · 2025Article
- Human Pluripotent Stem Cell-Derived Alveolar Organoids for Gene-editing and Lung Adenocarcinomas Modeling.International journal of biological sciences · 2025Article
- Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA.Molecular therapy. Nucleic acids · 2024Article
- Uncovering strain- and age-dependent innate immune responses to SARS-CoV-2 infection in air-liquid-interface cultured nasal epithelia.iScience · 2024Article
- Diet-induced obesity affects influenza disease severity and transmission dynamics in ferrets.Science advances · 2024Article
- Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment.PLoS medicine · 2024Article
- Macrophage-1 antigen exacerbates histone-induced acute lung injury and promotes neutrophil extracellular trap formation.FEBS open bio · 2024Article
- Protective role of the HSP90 inhibitor, STA-9090, in lungs of SARS-CoV-2-infected Syrian golden hamsters.BMJ open respiratory research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lung is the primary site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced immunopathology whereby the virus enters the host cells by binding to angiotensin-converting enzyme 2 (ACE2). Sophisticated regeneration and repair programs exist in the lungs to replenish injured cell populations. However, known resident stem/progenitor cells have been demonstrated to express ACE2, raising a substantial concern regarding the long-term consequences of impaired lung regeneration after SARS-CoV-2 infection. Moreover, clinical treatments may also affect lung repair from antiviral drug candidates to mechanical ventilation. In this review, we highlight how SARS-CoV-2 disrupts a program that governs lung homeostasis. We also summarize the current efforts of targeted therapy and supportive treatments for COVID-19 patients. In addition, we discuss the pros and cons of cell therapy with mesenchymal stem cells or resident lung epithelial stem/progenitor cells in preventing post-acute sequelae of COVID-19. We propose that, in addition to symptomatic treatments being developed and applied in the clinic, targeting lung regeneration is also essential to restore lung homeostasis in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.